Immunotherapeutic strategies like PIK3CG and PD-L1 targeted therapies can be particularly beneficial in the treatment of metaplastic breast cancers, especially in claudin-low breast cancers (CLBCs), which lack traditional treatment targets and can potentially improve patient outcomes [36]. Ongoing clinical trials are aiming at optimizing these combinations further, particularly in TNBC [36]. This evidence concerns the gene PIK3CG and breast cancer.